XOMA Royalty amends Ligand merger agreement to add holding company reorganization step

Filed May 18, 2026 · Period ending May 16, 2026 · ~1 min read

Key Changes

• high

  XOMA amended its merger agreement with Ligand Pharmaceuticals to add a newly formed subsidiary (HoldCo) as a party, enabling a holding company reorganization under Nevada law before the merger closes.

  Item 1.01 verify on EDGAR →
• medium

  The holding company reorganization is a new condition that must be completed before the Ligand merger can close, adding a structural step to the previously announced transaction.

  Item 1.01 verify on EDGAR →
• medium

  HoldCo is a wholly-owned subsidiary formed solely for this reorganization purpose and will become the surviving entity after Ligand's merger subsidiary merges into it.

  Item 1.01 verify on EDGAR →